Journal of Isfahan Medical School

Journal of Isfahan Medical School

Trend and inequality in the burden of tuberculosis associated with high fasting plasma glucose in Iran: Evidence from three decades of data (1990-2021)

Document Type : Original Article(s)

Authors
Ali Amiri 1
Victoria Momenabadi 2
Amirhoseen Sori 3
Elham Goodarzi 4
1 Assistant Professor, Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
2 Assistant Professor, Department of Public Health, School of Health, Bam University of Medical Sciences, Bam, Iran
3 Assistant Professor, Chamran Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran
4 PhD Student in Epidemiology, Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, AND,PhD Student in Epidemiology Social Determinants of Health Research Center, Iran University of Medical Sciences, Tehran, Iran
10.48305/jims.v44.i870.1218
Abstract
Background :Today, diabetes is one of the most common comorbidities and risk factors in patients with tuberculosis (TB). The present study examines the trend of the disease burden of TB attributed to high fasting plasma glucose (HFPG) in Iran during the years 1990 to 2021.
Methods: The present study analyzes data on mortality and DALYs from tuberculosis associated with high fasting blood glucose in Iran from 1990 to 2021. These data were extracted from the Global Burden of Disease Database (2021). In addition, the relationship of these items with the Human Development Index was measured by calculating Pearson's correlation.
Findings: The burden of TB disease attributed to HFPG in Iran has been decreasing during 1990-2021. Sistan and Baluchestan, Golestan, and Khorasan Razavi provinces showed the highest burden of TB attributed to HFPG, and Tehran province showed the highest percentage decrease in the burden change. There is a negative and significant correlation between the HDI and the DALY of TB attributed to HFPG (r=-0.378, p =0.035) and the YLD (Years Lived with Disability) attributed to HFPG (r=-0.449, P=0.011).
Conclusion: Although Iran has been successful in reducing the burden of TB attributed to HFPG, there are significant regional inequalities. Improving human development indicators and implementing targeted interventions in deprived areas can help further reduce this burden.

Highlights

Ali Amiri: Google Scholar , PubMed

Elham Goodarzi: Google Scholar , PubMed

Keywords
Tuberculosis
Diabetes Mellitus
Hyperglycemia
Socioeconomic Factors
Global Burden of Disease
Iran
Subjects
1.     Organization WH. Use of targeted next-generation sequencing to detect drug-resistant tuberculosis: rapid communication, July 2023: World Health Organization; 2023.
2.     Restrepo BI. Diabetes and tuberculosis. Understanding the host immune response against mycobacterium tuberculosis infection. Microbiol Spectr 2018: 1-21.
3.     Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011; 9: 1-15.
4.     Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011; 2011(1): 405310.
5.     Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K. The World Health Organization standards for tuberculosis care and management. European Respiratory Society; 2018.
6.     Magliano DJ, Boyko EJ, Atlas ID. COVID-19 and diabetes. IDF DIABETES ATLAS [Internet] 10th edi: International Diabetes Federation; 2021.
7.     Cao Y, Jin C, Zhang J, Sun H, Ma B, Yang X, et al. Diabetes burden, trends, and inequalities in western pacific region, 1990–2019: a population-based study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2023; 17(9): 102852.
8.     Brauer M, Roth GA, Aravkin AY, Zheng P, Abate KH, Abate YH, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403(10440): 2162-203.
9.     Conceição P. Human development report 2020-the next frontier: Human development and the anthropocene. United Nations Development Programme: Human Development Report. 2020.
10.  Tavakoli A. Incidence and prevalence of tuberculosis in Iran and neighboring countries. Zahedan J Res Med Sci 2017; 19(7): e9238.
11.  Mansoori N, Pahlavanzadeh B, Atarjalali M. Risk factors associated with multidrug-resistant tuberculosis in areas with a moderate tuberculosis burden. Int Health 2025; 17(2): 186-94.
12.  Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis 2021; 113 Suppl 1(Suppl 1): S7-S12.
13.  Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5(7): e152.
14.  Kashi JH, SayehMiri K, Javanian M, Asadollahi K. The Prevalence of Type-2 Diabetes and its Related Factors in Pulmonary‎ Tuberculosis (TB) Patients of North of Iran‎. J Biochem Tech 2019; 10(2): 131-7.
15.  Baghaei P, Tabarsi P, Marjani M, Moniri A, Masjedi MR. Screening for diabetes mellitus in tuberculosis patients in a referral center in Iran. Infect Dis (Lond) 2015; 47(7): 472-6.
16.  Alavi SM, Khoshkhoy MM. Pulmonary tuberculosis and diabetes mellitus: Co-existence of both diseases in patients admitted in a teaching hospital in the southwest of Iran. Caspian J Intern Med 2012; 3(2): 421-4.
17.  Sadeghi K, Poorolajal J, Doosti-Irani A. Prevalence of modifiable risk factors of tuberculosis and their population attributable fraction in Iran: A cross-sectional study. PLoS One 2022; 17(8): e0271511.
18.  Jimma W, Ghazisaeedi M, Shahmoradi L, Abdurahman AA, Kalhori SRN, Nasehi M, et al. Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta-analysis. Rev Soc Bras Med Trop 2017; 50(3): 287-95.
19.  Boutayeb A. The burden of communicable and non-communicable diseases in developing countries. In: Preedy VR, Watson RR, Editors. Handbook of disease burdens and quality of life measures. New York, NY: Springer; 2010. p. 531-46.
20.  Alavi SM, Bakhtiarinia P, Eghtesad M, Albaji A, Salmanzadeh S. A Comparative Study on the Prevalence and Risk Factors of Tuberculosis Among the Prisoners in Khuzestan, South-West Iran. Jundishapur J Microbiol 2014; 7(12): e18872.
21.  Okhovat-Isfahani B, Bitaraf S, Mansournia MA, Doosti-Irani A. Inequality in the global incidence and prevalence of tuberculosis (TB) and TB/HIV according to the human development index. Med J Islam Repub Iran 2019; 33: 45.
22.  Rodríguez-Morales AJ, Castañeda-Hernández DM. Relationships between morbidity and mortality from tuberculosis and the human development index (HDI) in Venezuela, 1998–2008. I Int J Infect Dis 2012; 16(9): e704-e5.
23.  Goodarzi E, Sohrabivafa M, Dehkordi AH, Moayed L, Khazaei Z. Effect of human development index on tuberculosis incidence in Asia: An ecological study. Advances in Human Biology 2019; 9(3): 251-7.
24.  Fujita DM, Alvarenga RF, de Andrade Jr HF. Trends in tuberculosis and inequality-adjusted Human Development Index in Brazil, 2018–2022. J Public Health Pol 2025; 46, 139–48.
25.  Shewade HD, Jeyashree K, Mahajan P, Shah AN, Kirubakaran R, Rao R, et al. Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review. PLoS One 2017; 12(10): e0186697.
Journal of Isfahan Medical School
Volume 44, Issue 870
2nd Week, September
September and October 2026
Pages 1218-1229

  • Receive Date 17 July 2025
  • Accept Date 27 June 2026